Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients

Cancer Science

Volumn 106, Issue 3, 2015, Pages 324-327

  Taniguchi, Hiroya ^a   Yamazaki, Kentaro ^b   Yoshino, Takayuki ^c   Muro, Kei ^a   Yatabe, Yasushi ^a   Watanabe, Toshiaki ^d   Ebi, Hiromichi ^e   Ochiai, Atsushi ^f   Baba, Eishi ^g   Tsuchihara, Katsuya ^h  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h NATIONAL CANCER CENTER   (Japan)

Author keywords

Anti EGFR antibodies; Colorectal cancer; Guideline; K ras genes; N ras genes

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PANITUMUMAB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PARAFFIN; RAS PROTEIN;

ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; GENE MUTATION; HUMAN; IN VITRO STUDY; JAPANESE (PEOPLE); LIMIT OF DETECTION; ONCOGENE K RAS; ONCOGENE N RAS; ONCOLOGY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THERAPY EFFECT; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DNA SEQUENCE; GENETIC SCREENING; GENETICS; IMMUNOLOGY; JAPAN; MUTATION; PROCEDURES; STAINING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENETIC TESTING; GTP PHOSPHOHYDROLASES; HUMANS; JAPAN; MEMBRANE PROTEINS; MUTATION; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; STAINING AND LABELING;

EID: 84925635283     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12595     Document Type: Article

References (10)

1. Japanese Society of Medical Oncology. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients (1 screen). [Cited 10 Apr 2014.] Available from URL: http://www.jsmo.or.jp/file/dl/newsj/1288.pdf.
2. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34.
3. Schwartzberg LS, Rivera F, Karthaus M et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-7.
4. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 17-65.
5. Tejpar S, Celik I, Schlichting M et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7.
6. Peeters M, Douillard JY, Van Cutsem E et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-65.
7. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
8. Kudo T, Satoh T, Muro K et al. Clinical validation of a novel multiplex kit for all RAS mutations in colorectal cancer: results of RASKET (RAS KEy Testing) prospective multicenter study. WCGIC 2014, P-0195
9. Baas JM, Krens LL, Guchelaar HJ et al. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011; 16: 1239-49.
10. Franklin WA, Haney J, Sugita M et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010; 12: 43-50.